Member Login
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • AstraZeneca PLC (LSE: AZN) Latest News

    Investing Videos

    A Closer Look At AstraZeneca plc

    | Jill Ralph

    VIDEO: Two Fools analyse AstraZeneca plc (LON: AZN).

    Read more »

    Company Comment

    Earnings Drop 16% At AstraZeneca Plc

    | Nate Weisshaar

    Investing the future while revenues fall takes its toll on the bottom line at AstraZeneca plc (LON:AZN).

    Read more »

    Investing Articles

    Why You Might Think Of Investing In This FTSE Underdog: AstraZeneca plc

    | Tony Reading

    AstraZeneca plc (LON: AZN) could be a contrarian investment opportunity.

    Read more »

    Investing Articles

    Why Reinvesting Your Dividends Is The Best Decision You’ll Ever Make

    | Rupert Hargreaves

    Dividend reinvestment is a great way to achieve market beating returns without much effort.

    Read more »

    Company Comment

    2 Big Problems For GlaxoSmithKline Plc

    | Leo Sun

    It's been a rough year for pharmaceutical giant GlaxoSmithKline plc (LON: GSK).

    Read more »

    Investing Articles

    4 Ways AstraZeneca plc Will Continue To Lead The Biotechnology Sector

    | Rupert Hargreaves

    How does AstraZeneca plc (LON: AZN) compare to its sector peers?

    Read more »

    Investing Articles

    Why I Hate AstraZeneca plc

    | Harvey Jones

    Aside from its 5.6% yield, Harvey Jones finds little to love about AstraZeneca plc (LON: AZN).

    Read more »

    Investing Articles

    4 Ways GlaxoSmithKline plc Will Continue To Lag The Biotechnology Sector

    | Rupert Hargreaves

    How does GlaxoSmithKline plc (LON: GSK) compare to its sector peers?

    Read more »

    Investing Articles

    21 Worrying Reasons Which Make AstraZeneca plc A Sell

    | Royston Wild

    Royston Wild reveals why shares in AstraZeneca plc (LON: AZN) are ready to shuttle lower.

    Read more »

    Investing Articles

    News Flow Makes Me Want To Buy AstraZeneca plc

    | Peter Stephens

    I’m thinking of buying AstraZeneca plc (LON: AZN) and here’s why…

    Read more »

    Investing Articles

    Neil Woodford: The Surprising Hero Of British Biotech

    | G A Chester

    Funding for British biotech has been drying up, but ace City investor Neil Woodford has ridden to the rescue.

    Read more »

    Investing Articles

    This Ratio Explains Why I’d Buy AstraZeneca plc Today

    | Roland Head

    AstraZeneca plc (LON:AZN) offers a 5.4% yield, but there's a more compelling reason to buy this firm's shares, as Roland…

    Read more »